Ex­elix­is throws in the tow­el on ear­ly-stage liv­er can­cer af­ter fi­nal read­out shows OS flop

The door to a la­bel ex­pan­sion for Ex­elix­is’ Cabome­tyx is now ful­ly shut.

Ex­elix­is kept a sliv­er of hope — how­ev­er slim — back in the sum­mer of last year, when it post­ed mixed re­sults from an in­ter­im read­out of a Phase III tri­al test­ing a com­bi­na­tion of Cabome­tyx and Roche’s Tecen­triq against Bay­er’s Nex­avar in pre­vi­ous­ly un­treat­ed liv­er can­cer. But the fi­nal analy­sis proved just as dis­ap­point­ing, as the com­bo was linked to “nei­ther im­prove­ment nor detri­ment in OS.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER